Analysts Offer Predictions for Travere Therapeutics, Inc.’s Q4 2025 Earnings (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for Travere Therapeutics in a research note issued to investors on Friday, October 11th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of $0.30 for the quarter, up from their previous forecast of $0.25. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.95) per share.

Other equities research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. lifted their price objective on shares of Travere Therapeutics from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Guggenheim raised their price target on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright cut their price objective on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 target price on shares of Travere Therapeutics in a research report on Tuesday, October 8th. Finally, Wedbush increased their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.75.

Travere Therapeutics Trading Down 4.1 %

NASDAQ TVTX opened at $16.41 on Monday. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $18.60. The stock’s 50-day moving average price is $11.78 and its 200-day moving average price is $8.98. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million for the quarter, compared to analysts’ expectations of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%.

Insider Activity

In related news, CEO Eric M. Dube sold 21,125 shares of Travere Therapeutics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $243,360.00. Following the completion of the transaction, the chief executive officer now directly owns 361,975 shares in the company, valued at approximately $4,169,952. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Christopher R. Cline sold 2,490 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $28,684.80. Following the sale, the chief financial officer now directly owns 74,595 shares of the company’s stock, valued at $859,334.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric M. Dube sold 21,125 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $243,360.00. Following the sale, the chief executive officer now owns 361,975 shares in the company, valued at $4,169,952. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,707 shares of company stock valued at $1,504,312 in the last quarter. 3.75% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. lifted its position in shares of Travere Therapeutics by 912.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock valued at $18,200,000 after buying an additional 1,995,419 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Travere Therapeutics by 79.2% in the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock valued at $1,423,000 after purchasing an additional 81,611 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Travere Therapeutics during the first quarter worth about $452,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Travere Therapeutics during the 4th quarter worth about $5,711,000. Finally, Acadian Asset Management LLC lifted its stake in Travere Therapeutics by 202.6% in the 2nd quarter. Acadian Asset Management LLC now owns 144,901 shares of the company’s stock valued at $1,190,000 after buying an additional 97,020 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.